Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 22, Issue 1, 2010, Pages 54-61

  Potard, Valérie ^a,b   Chassany, Olivier ^c   Lavignon, Marc ^d   Costagliola, Dominique ^a,b,e   Spire, Bruno ^f,g,h  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d BOEHRINGER INGELHEIM   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f AIX MARSEILLE UNIV   (France)

^g AIX MARSEILLE UNIVERSITY   (France)

^h OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

Author keywords

Antiretroviral therapy; Health related quality of life; WHOQoL

Indexed keywords

ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; ANXIETY; ARTICLE; DEPRESSION; DRUG EFFICACY; FEMALE; HEALTH CARE QUALITY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDEPENDENCE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OBSERVATIONAL STUDY; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELIGION; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANXIETY; BENZOXAZINES; DEPRESSION; FEMALE; FRANCE; HEALTH STATUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77949641709     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120903033250     Document Type: Article

References (24)

1. Barczak, P., Kane, N., Andrews, S., Congdon, A.M., Clay, J.C., & Betts, T. (1988). Patterns of psychiatric morbidity in agenito-urinary clinic. A validation of the hospital anxiety depression scale (HAD). The British Journal of Psychiatry, 152, 698-700.
2. Barreiro, P., Soriano, V., Blanco, F., Casimiro, C., de la Cruz, J.J., & Gonzalez-Lahoz, J. (2000). Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS, 14, 807-812.
3. Calza, L., Manfredi, R., Colangeli, V., Tampellini, L., Sebastiani, T., Pocaterra, D., et al. (2005). Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS, 19, 1051-1058.
4. Carr, A., Hudson, J., Chuah, J., Mallal, S., Law, M., Hoy, J., et al. (2001). HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS, 15, 1811-1822.
5. Carr, A., Samaras, K., Thorisdotir, A., Kaufmann, G., Chisholm, D., & Cooper, D. (1999). Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study. Lancet, 353, 2093-2099.
6. Carrieri, M.P., Leport, C., Protopopesccu, C., Cassuto, J.P., Bouvet, E., Peyramond, D., et al. (2006). Factors associated with nonadherence to higly active antiretroviral therapy: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. Journal of AIDS, 32, 38-47.
7. Carrieri, M.P., Spire, B., Durand, S., Katlama, C., Peyramond, D., Franc¸ois, C., et al. (2003). Health-related quality of life after 1 year of highly active antiretroviral therapy. Journal of AIDS, 41, 477-485.
8. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum.
9. Duran, S., Save` s, M., Spire, B., Cailleton, V., Sobel, A., Carrieri P., et al. (2001). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS, 15, 2441-2444.
10. Fisac, C., Fumero, E., Crespo, M., Roson, B., Ferrer, E., Virgili, N., et al. (2005). Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS, 19, 917-925.
11. Hsiung, P.C., Fang, C.T., Chang, Y.Y., Chen, M.Y., & Wang, J.D. (2005). Comparison of WHOQOL-Bref and SF-36 in patients with HIV infection. Quality of Life Research, 14(1), 141-150.
12. Justice, A.C., Holmes, W., Gifford, A.L., Rabeneck, L., Zackin, R., Sinclair, G., et al. (2001). Development and validation of a self-completed HIV symptom index. Journal of Clinical Epidemiology, 54, S77-S90.
13. Martinez, E., Arnaiz, J.A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., et al. (2003). Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. The New England Journal of Medicine, 349, 1036-1046.
14. Negredo, E., Cruz, L., Paredes, R., Ruiz, L., Fumas, C.R., Bonjoch, A., et al. (2002). Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clinical Infectious Diseases, 34, 504-510.
15. Nicholas, P.K., Kirksey, M., Corless, I.B., & Kemppainen, J. (2005). Lipodystrophy and quality of life in HIV: Symptom management issues. Applied Nursing Research, 18, 55-58.
16. Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The New England Journal of Medicine, 338, 853-860.
17. Préau, M., Marcellin, F., Carrieri, M.P., Lert, F., Obadia, Y., & Spire, B. (2007). Health-related quality of life in French people living with HIV in 2003: Results from the national ANRS-EN12-VESPA Study. AIDS, 21(Suppl. 1), S19-S27.
18. Ruiz, L., Negredo, E., Pere, D., Paredes, R., Esthert, F., Balague, M., et al. (2001). Antiretroviral treatment simplification with nevirapine in protease inhibitors experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Journal of AIDS, 27, 229-236.
19. Spire, B., Marcellin, F., Cohen-Codar, I., Flandre, P., Boué , F., Dellamonica, P., et al. (2008). Impact of Lopinavir monotherapy on quality of life and selfreported symptoms among antiretroviral-naive patients: Results of the MONARK trial. Antiviral Therapy, 13(4), 591-599.
20. US Centers for Disease Control and Prevention (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recommendations Reports, 41(RR-17), 1-19.
21. Van Walraven, C., Mahon, J.L., Moher, D., Bohm, C., & Laupacis, A. (1999). Surveying physicians to determine the minimal important difference: Implications for sample size calculation. Journal of Clinical Epidemiology, 52(8), 717-723.
22. Ware, J.E., Kosinski, M., Turner-Bowker, D.M., & Gandek, B. (2005). How to score version 2 of the SF-12 Health Survey (with a supplement documenting version1). Boston, MA: QualityMetric Incorporated Lincoln, Rhode Island and Health Assessment Lab.
23. The WHOQOL-HIV Group(2002). WHOQOL-HIV instrument. Users manual. Scoring and coding for the WHOQOL-HIV instruments. Geneva, Switzerland: Department of Mental Health and Substance Dependence, World Health Organization.
24. Zigmond, A.S., & Snaith, R.P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67, 361-370.